Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 2, 2005, Pages 88-94

  Cannon III, Richard O ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Myocardial infarction; Myocardial ischemia; Preconditioning; Reperfusion injury; Superoxide anions

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; CARIPORIDE; ENIPORIDE; FIBRINOLYTIC AGENT; FREE RADICAL; GLUCOSE; INSULIN; LIDOCAINE; NICORANDIL; PEXELIZUMAB; PLACEBO; POTASSIUM; RECOMBINANT ENZYME; SUPEROXIDE DISMUTASE; TRIBUZONE;

ACUTE HEART INFARCTION; CELL PROTECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOTOXICITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG FATALITY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART REINFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HUMAN; NONHUMAN; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTON SODIUM EXCHANGE; REPERFUSION INJURY; REVIEW; SHOCK; STENT; STROKE; SURVIVAL;

ANIMALS; APOPTOSIS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL REVASCULARIZATION; MYOCARDIUM; PROGNOSIS; SUPEROXIDES;

EID: 20344401109     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0096     Document Type: Review

References (55)

1. Schomig A et al. (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 343: 385-391
2. Montalescot G et al. (2001) Platelet glycoprotein IIb/IIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895-1903
3. Schomig A et al. (2003) Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 108: 1084-1088
4. Jennings RB et al. (1990) Development of cell injury in sustained acute ischemia. Circulation 82(suppl): II2-II12
5. Neri Serneri GG et al. (2003) Immunomediated and ischemia-independent inflammation of coronary microvessels in unstable angina. Circ Res 92: 1359-1366
6. Abbate A et al. (2004) Widespread myocardial inflammation and infarct-related artery patency. Circulation 110: 46-50
7. Frangogiannis NG et al. (2002) The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31-47
8. Semenza GL (2000) Cellular and molecular dissection of reperfusion injury: ROS within and without. Circ Res 86: 117-118
9. Rezkalla SH and Kloner RA (2002) No-reflow phenomenon. Circulation 105: 656-662
10. Bialik S et al. (1999) The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 85: 403-414
11. Bielawska AE et al. (1997) Ceramide is involved in triggering of cardiomyocyte apoptosis induced by ischemia and reperfusion. Am J Pathol 151: 1257-1263
12. Krijnen PAJ et al. (2002) Apoptosis in myocardial ischemia and infarction. J Clin Pathol 55: 801-811
13. Zhao ZQ et al. (2000) Reperfusion induces myocardial apoptotic cell death. Cardiovasc Res 45: 651-660
14. Saraste A et al. (1997) Apoptosis in human acute myocaridal infarction. Circulation 95: 320-323
15. Olivetti G et al. (1996) Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 28: 2005-2016
16. Williams RS and Benjamin IJ (2002) Protective responses in the ischemic myocardium. J Clin Invest 106: 813-818
17. Murry CE et al. (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136
18. Sasaki N et al. (2000) Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101: 439-445
19. Jung F et al. (2000) Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 86: 319-325
20. Rossig L et al. (1999) Nitric oxide inhibits caspase-3 by S-nitrosation in vivo. J Biol Chem 274: 6823-6826
21. Moon C et al. Erythropoietin reduces myocardial infarction and left ventricular decline and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 100: 11612-11617
22. Parsa CJ et al. (2003) A novel protective effect of erythropoeitin in the infarcted heart. J Clin Invest 112: 999-1007
23. Radford NB et al. (1996) Cardioprotective effects of 70-kDa heat shock protein transgenic mice. Proc Natl Acad Sci U S A 93: 2339-2342
24. Martin JL et al. (1997) Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 96: 4343-4348
25. Marber MS et al. (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264-1272
26. Hoshida S et al. (1993) Sublethal ischemia alters myocardial antioxidant activity in canine heart. Am J PPhysiol 33: H33-H39
27. Braunwald E and Kloner RA (1982) The stunned myocardium: prolonged, post-ischemic ventricular dysfuction.. Circulation 66: 1146-1149
28. Charlat ML et al. (1989) Prolonged abnormalities of left ventricular diastolic wall thinning in the 'stunned' myocardium in conscious dogs: time course and relation to systolic dysfunction. J Am Coll Cardiol 13: 185-194
29. Kloner RA and Jennings RB (2001) Consequences of brief ischemia: Stunning, precoditioning, and their clinical implications. Part 1. Circulation 104: 2981-2989
30. Bolli R et al. (1989) Direct evidence that oxygenderived free radicals contribute to postiscchemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A 86: 4695-4699
31. Przyklenk K and Kloner RA (1986) Superoxide dismutase plus catalase improve contractile function in the canine model of the 'stunned myocardium'. Circ Res 58: 148-156
32. Bolli R et al. (2004) Myocardial protection at a crossroads. The need for translation into clinical practice. Circulation 95: 125-134
33. Kloner RA and Rezkalla SH (2004) Cardiac protection during acute myocardial infarction: Where do we stand in 2004? J Am Coll Cardiol 44: 276-286
34. Garrat KN et al. (1998) Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J 136: 196-204
35. Mahaffey KW et al. (1999) Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of an multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarct STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34: 1711-1720
36. Quintana M et al. (2003) Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol 59: 1-9
37. Ross A et al. (2002) Acute Myocardial Infarction STudy of ADenosine (AMISTAD II). J Am Coll Cardiol 39 (Suppl 2): 338A
38. Kopecky SL et al. (2003) A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of and adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J 146: 146-152
39. Marzilli M et al. (2000) Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 101: 2154-2159
40. Sodi-Pallares D et al. (1962) Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 9: 166-181
41. Fath-Ordoubadi F and Beatt KJ (1997) Gluccose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96: 1152-1156
42. Diaz R et al. (1998) Metabolic modulation of acute myocardial infarction. The ECLA Glucose-insulin-potassium pilot trial. Circulation 98 2227-2234
43. Van der Horst ICC et al. (2003) Glucose-insulin-potassium infusion in patients teated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 42: 784-791
44. Pache J et al. (2004) A randomized evaluation of the effects of glucose-insulin-potassium infusion non myocardial salvage in patients wwith acute myocardial infarction treated with reperfusion theraapy. Am Heart J 48: G1-G6
45. + exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA. Circulation 101: 2902-2908
46. + exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarcton. Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) Trial. J Am Coll Cardiol 38: 1644-1650
47. Sakata Y et al. (1997) Salutory effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients acute myocardial infarction. Am Heart J 133: 616-621
48. Ito H et al. (1999) Intravenous nicorandil can preserve microvascular integrity and myocardial viability patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 33: 654-660
49. Flaherty JT et al. (1994) Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 89: 1982-1991
50. The EMIP-FR Group (2000) Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocarial infarction, with and without thrombolytic therapy. A double-blind, placebo-controlled, randomized trial. Eur Heart J 21: 1537-1546
51. Baran KW et al. (2001) Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study. Circulation 104: 2778-2783
52. Faxon DP et al. (2002) The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. J Am Coll Cardiol 40: 1199-1204
53. de Zwaan C et al. (2002) Continuous 48-h C1 -inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 23: 1670-1677
54. Mahaffey KW et al. (2003) Effect of Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction. The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108: 1176-1183
55. Granger CB et al. (2003) Pexelizumab, and anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108: 1184-1190